{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T08:25:42Z","timestamp":1792743942494,"version":"4.5.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T00:00:00Z","timestamp":1766102400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T00:00:00Z","timestamp":1769040000000},"content-version":"vor","delay-in-days":34,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Women's Health"],"DOI":"10.1186\/s12905-025-04227-8","type":"journal-article","created":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T02:14:42Z","timestamp":1766110482000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Exploring Nectin-4 as a potential diagnostic biomarker in endometrial adenocarcinoma"],"prefix":"10.1186","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8863-817X","authenticated-orcid":false,"given":"Melike","family":"Ordu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9811-2726","authenticated-orcid":false,"given":"Serife Ozlem","family":"Genc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,19]]},"reference":[{"key":"4227_CR1","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1186\/s12967-020-02554-y","volume":"18","author":"D Br\u00fcggmann","year":"2020","unstructured":"Br\u00fcggmann D, Ouassou K, Klingelh\u00f6fer D, Bohlmann MK, Jaque J, Groneberg DA. Endometrial cancer: mapping the global landscape of research. J Transl Med. 2020;18:386. https:\/\/doi.org\/10.1186\/s12967-020-02554-y.","journal-title":"J Transl Med"},{"key":"4227_CR2","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1186\/s40364-021-00310-y","volume":"9","author":"M Yi","year":"2021","unstructured":"Yi M, Li T, Niu M, Luo S, Chu Q, Wu K. Epidemiological trends of women\u2019s cancers from 1990 to 2019 at the global, regional, and national levels: a population-based study. Biomark Res. 2021;9:55. https:\/\/doi.org\/10.1186\/s40364-021-00310-y.","journal-title":"Biomark Res"},{"issue":"6","key":"4227_CR3","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1038\/modpathol.2015.43","volume":"28","author":"E Stelloo","year":"2015","unstructured":"Stelloo E, Bosse T, Nout RA, MacKay HJ, Church DN, Nijman HW, et al. Refining prognosis and identifying targetable pathways for high-risk endometrial cancer; a TransPORTEC initiative. Mod Pathol. 2015;28(6):836\u201344. https:\/\/doi.org\/10.1038\/modpathol.2015.43.","journal-title":"Mod Pathol"},{"issue":"7447","key":"4227_CR4","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1038\/nature12113","volume":"497","author":"C Kandoth","year":"2013","unstructured":"Cancer Genome Atlas Research Network, Kandoth C, Schultz N, Cherniack AD, Akbani R, Liu Y, et al. Integrated genomic characterization of endometrial carcinoma. Nature. 2013;497(7447):67\u201373. https:\/\/doi.org\/10.1038\/nature12113.","journal-title":"Nature"},{"issue":"5","key":"4227_CR5","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1093\/annonc\/mdy058","volume":"29","author":"S Kommoss","year":"2018","unstructured":"Kommoss S, McConechy MK, Kommoss F, Leung S, Bunz A, Magrill J, et al. Final validation of the ProMisE molecular classifier for endometrial carcinoma in a large population-based case series. Ann Oncol. 2018;29(5):1180\u20138. https:\/\/doi.org\/10.1093\/annonc\/mdy058.","journal-title":"Ann Oncol"},{"issue":"6","key":"4227_CR6","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13061478","volume":"13","author":"M Alexa","year":"2021","unstructured":"Alexa M, Hasenburg A, Battista MJ. The TCGA molecular classification of endometrial cancer and its possible impact on adjuvant treatment decisions. Cancers (Basel). 2021;13(6):1478. https:\/\/doi.org\/10.3390\/cancers13061478.","journal-title":"Cancers (Basel)"},{"key":"4227_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2021.174473","volume":"910","author":"S Chatterjee","year":"2021","unstructured":"Chatterjee S, Sinha S, Kundu CN. Nectin cell adhesion molecule-4 (NECTIN-4): a potential target for cancer therapy. Eur J Pharmacol. 2021;910:174473. https:\/\/doi.org\/10.1016\/j.ejphar.2021.174473.","journal-title":"Eur J Pharmacol"},{"issue":"16","key":"4227_CR8","doi-asserted-by":"publisher","first-page":"6694","DOI":"10.1158\/0008-5472.CAN-09-0016","volume":"69","author":"A Takano","year":"2009","unstructured":"Takano A, Ishikawa N, Nishino R, Masuda K, Yasui W, Inai K, et al. Identification of Nectin-4 oncoprotein as a diagnostic and therapeutic target for lung cancer. Cancer Res. 2009;69(16):6694\u2013703. https:\/\/doi.org\/10.1158\/0008-5472.CAN-09-0016.","journal-title":"Cancer Res"},{"key":"4227_CR9","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s13046-015-0139-9","volume":"34","author":"S Nishiwada","year":"2015","unstructured":"Nishiwada S, Sho M, Yasuda S, Shimada K, Yamato I, Akahori T, et al. Nectin-4 expression contributes to tumor proliferation, angiogenesis, and patient prognosis in human pancreatic cancer. J Exp Clin Cancer Res. 2015;34:30. https:\/\/doi.org\/10.1186\/s13046-015-0139-9.","journal-title":"J Exp Clin Cancer Res"},{"key":"4227_CR10","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1140578","volume":"13","author":"R Liu","year":"2023","unstructured":"Liu R, Zhao K, Wang K, Chen J, Liu J, Li L. Prognostic value of Nectin-4 in human cancers: a meta-analysis. Front Oncol. 2023;13:1140578. https:\/\/doi.org\/10.3389\/fonc.2023.1140578.","journal-title":"Front Oncol"},{"key":"4227_CR11","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1377452","volume":"14","author":"K Li","year":"2024","unstructured":"Li K, Zhou Y, Zang M, Jin X, Li X. Therapeutic prospects of Nectin-4 in cancer: applications and value. Front Oncol. 2024;14:1377452. https:\/\/doi.org\/10.3389\/fonc.2024.1377452.","journal-title":"Front Oncol"},{"issue":"1","key":"4227_CR12","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15010110","volume":"15","author":"HK Chang","year":"2023","unstructured":"Chang HK, Park YH, Choi JA, Kim HS, Kim JH, Lee JH. Nectin-4 as a predictive marker for poor prognosis of endometrial cancer with mismatch repair impairment. Cancers (Basel). 2023;15(1):110. https:\/\/doi.org\/10.3390\/cancers15010110.","journal-title":"Cancers (Basel)"},{"issue":"49","key":"4227_CR13","doi-asserted-by":"publisher","first-page":"83460","DOI":"10.18632\/oncotarget.13046","volume":"7","author":"KLM Boylan","year":"2016","unstructured":"Boylan KLM, Buchanan PC, Manion RD, Shukla DM, Braundmeier-Fleming A, Skubitz APN. The expression of Nectin-4 on the surface of ovarian cancer cells alters their ability to adhere, migrate, aggregate, and proliferate. Oncotarget. 2016;7(49):83460\u201370. https:\/\/doi.org\/10.18632\/oncotarget.13046.","journal-title":"Oncotarget"},{"key":"4227_CR14","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.2147\/OTT.S370900","volume":"15","author":"J Hoffman-Censits","year":"2022","unstructured":"Hoffman-Censits J, Maldonado L. Targeted treatment of locally advanced and metastatic urothelial cancer: enfortumab vedotin in context. Onco Targets Ther. 2022;15:1519\u201328. https:\/\/doi.org\/10.2147\/OTT.S370900.","journal-title":"Onco Targets Ther"},{"key":"4227_CR15","doi-asserted-by":"publisher","first-page":"142","DOI":"10.3389\/fmed.2019.00142","volume":"6","author":"SD Soysal","year":"2019","unstructured":"Soysal SD, Piscuoglio S, Ng CKY, et al. Nectin-4 expression is an independent prognostic biomarker and associated with better survival in triple-negative breast cancer. Front Med (Lausanne). 2019;6:142. https:\/\/doi.org\/10.3389\/fmed.2019.00142.","journal-title":"Front Med (Lausanne)"},{"key":"4227_CR16","doi-asserted-by":"publisher","DOI":"10.1200\/PO.23.00345","author":"L Marandino","year":"2024","unstructured":"Marandino L, Crupi E, Costa de Padua T, et al. Nectin-4 positivity in genitourinary malignancies: a systematic review. JCO Precis Oncol. 2024. https:\/\/doi.org\/10.1200\/PO.23.00345.","journal-title":"JCO Precis Oncol"},{"issue":"3","key":"4227_CR17","doi-asserted-by":"publisher","first-page":"678","DOI":"10.3390\/cancers14030678","volume":"14","author":"S Rodler","year":"2022","unstructured":"Rodler S, Eismann L, Schlenker B, et al. Expression of Nectin-4 in variant histologies of bladder cancer and its prognostic value. Cancers (Basel). 2022;14(3):678. https:\/\/doi.org\/10.3390\/cancers14030678.","journal-title":"Cancers (Basel)"},{"issue":"4","key":"4227_CR18","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1097\/PGP.0000000000000243","volume":"35","author":"AM Schultheis","year":"2016","unstructured":"Schultheis AM, Martelotto LG, De Filippo MR, Piscuglio S, Ng CK, Hussein YR, et al. TP53 mutational spectrum in endometrioid and serous endometrial cancers. Int J Gynecol Pathol. 2016;35(4):289\u2013300. https:\/\/doi.org\/10.1097\/PGP.0000000000000243.","journal-title":"Int J Gynecol Pathol"},{"issue":"10","key":"4227_CR19","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1038\/s41379-022-01102-x","volume":"35","author":"L Vermij","year":"2022","unstructured":"Vermij L, L\u00e9on-Castillo A, Singh N, Powell ME, Edmondson RJ, Genestie C, et al. P53 immunohistochemistry in endometrial cancer: clinical and molecular correlates in the PORTEC-3 trial. Mod Pathol. 2022;35(10):1475\u201383. https:\/\/doi.org\/10.1038\/s41379-022-01102-x.","journal-title":"Mod Pathol"},{"key":"4227_CR20","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.35316","author":"DJ Martini","year":"2024","unstructured":"Martini DJ, Case KB, Gratz D, Pellegrini K, Beagle E, et al. PD-L1 and Nectin-4 expression and genomic characterization of bladder cancer with divergent differentiation. Cancer. 2024. https:\/\/doi.org\/10.1002\/cncr.35316.","journal-title":"Cancer"},{"key":"4227_CR21","doi-asserted-by":"publisher","DOI":"10.1200\/PO.23.00287","author":"ZI Ozay","year":"2024","unstructured":"Ozay ZI, Chehade CH, Agarwal N, et al. Assessing Nectin-4 as a predictive biomarker in urothelial carcinoma and other genitourinary malignancies. JCO Precis Oncol. 2024. https:\/\/doi.org\/10.1200\/PO.23.00287.","journal-title":"JCO Precis Oncol"},{"issue":"9","key":"4227_CR22","doi-asserted-by":"publisher","first-page":"2601","DOI":"10.31557\/APJCP.2019.20.9.2601","volume":"20","author":"AA Hashmi","year":"2019","unstructured":"Hashmi AA, Mudassir G, Hashmi RN, Irfan M, Asif H, Khan EY, et al. Microsatellite instability in endometrial carcinoma by immunohistochemistry is associated with clinical and histopathological parameters. Asian Pac J Cancer Prev. 2019;20(9):2601\u20137. https:\/\/doi.org\/10.31557\/APJCP.2019.20.9.2601.","journal-title":"Asian Pac J Cancer Prev"},{"issue":"3","key":"4227_CR23","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1038\/s41416-022-02063-3","volume":"128","author":"HF Berg","year":"2023","unstructured":"Berg HF, Engerud H, Myrvold M, Lien HE, Hjelmeland ME, Halle MK, et al. Mismatch repair markers in preoperative and operative endometrial cancer samples: expression concordance and prognostic value. Br J Cancer. 2023;128(3):492\u2013502. https:\/\/doi.org\/10.1038\/s41416-022-02063-3.","journal-title":"Br J Cancer"},{"issue":"8","key":"4227_CR24","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1097\/PAS.0000000000000425","volume":"39","author":"B Dudley","year":"2015","unstructured":"Dudley B, Brand RE, Thull D, Bahary N, Nikiforova MN. Germline MLH1 mutations in Lynch syndrome patients with colorectal and endometrial carcinoma demonstrating isolated loss of PMS2 expression. Am J Surg Pathol. 2015;39(8):1114\u201320. https:\/\/doi.org\/10.1097\/PAS.0000000000000425.","journal-title":"Am J Surg Pathol"},{"issue":"6","key":"4227_CR25","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1097\/PAS.0000000000000606","volume":"40","author":"A Kato","year":"2016","unstructured":"Kato A, Sato N, Sugawara T, Takahashi K, Kito M, et al. Isolated loss of PMS2 immunohistochemical expression is frequently caused by heterogenous MLH1 promoter hypermethylation in Lynch syndrome screening for endometrial cancer patients. Am J Surg Pathol. 2016;40(6):770\u20136. https:\/\/doi.org\/10.1097\/PAS.0000000000000606.","journal-title":"Am J Surg Pathol"},{"key":"4227_CR26","doi-asserted-by":"publisher","first-page":"1628979","DOI":"10.3389\/fimmu.2025.1628979","volume":"16","author":"C Wang","year":"2025","unstructured":"Wang C, Feng M, Kou Y, Kuang W, Wang W, Liang D. Evaluation of microsatellite instability patterns in mismatch repair deficiency: a retrospective analysis of 285 endometrial cancers. Front Immunol. 2025;16:1628979. https:\/\/doi.org\/10.3389\/fimmu.2025.1628979.","journal-title":"Front Immunol"},{"issue":"1","key":"4227_CR27","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1111\/his.14015","volume":"76","author":"L Vermij","year":"2020","unstructured":"Vermij L, Smit V, Nout R, Bosse T. Incorporation of molecular characteristics into endometrial cancer management. Histopathology. 2020;76(1):52\u201363. https:\/\/doi.org\/10.1111\/his.14015.","journal-title":"Histopathology"},{"key":"4227_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2025.01.004","author":"Y Nakamura","year":"2025","unstructured":"Nakamura Y, Tanaka H, Numao N, et al. Enfortumab Vedotin for metastatic urothelial carcinoma: outcomes from a multicenter real-world study (YUSHIMA). Clin Genitourin Cancer. 2025. https:\/\/doi.org\/10.1016\/j.clgc.2025.01.004.","journal-title":"Clin Genitourin Cancer"},{"key":"4227_CR29","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.01472","author":"N Kl\u00fcmper","year":"2024","unstructured":"Kl\u00fcmper N, Darr C, B\u00fcttner T, Holzwarth N, Biernath N, et al. Subgroup analysis of real-world efficacy of enfortumab Vedotin in patients with metastatic\/locally advanced urothelial carcinoma from a European database. J Clin Oncol. 2024. https:\/\/doi.org\/10.1200\/JCO.23.01472.","journal-title":"J Clin Oncol"},{"key":"4227_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijgo.2025.01.105","author":"O Hooks","year":"2025","unstructured":"Hooks O. Theranostic implications of Nectin-4 oncoprotein in gynecologic cancers: a review. Int J Gynaecol Obstet. 2025. https:\/\/doi.org\/10.1016\/j.ijgo.2025.01.105.","journal-title":"Int J Gynaecol Obstet"},{"key":"4227_CR31","doi-asserted-by":"publisher","DOI":"10.3390\/biomolecules1501234","volume":"15","author":"Y Qiao","year":"2025","unstructured":"Qiao Y, Wang X, Chen L, Zhao R. Research hotspots and frontier analysis of Nectin-4 as a novel prognostic biomarker in endometrial carcinoma. Biomolecules. 2025;15:1234. https:\/\/doi.org\/10.3390\/biomolecules1501234.","journal-title":"Biomolecules"},{"key":"4227_CR32","doi-asserted-by":"publisher","DOI":"10.1111\/bju.16200","author":"T Kijima","year":"2025","unstructured":"Kijima T, Takada-Owada A, Shimoda H, et al. Predictive role of ABC transporters in the efficacy of enfortumab Vedotin for urothelial carcinoma. BJU Int. 2025. https:\/\/doi.org\/10.1111\/bju.16200.","journal-title":"BJU Int"},{"key":"4227_CR33","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-020-02525-2","volume":"18","author":"D Br\u00fcggmann","year":"2020","unstructured":"Br\u00fcggmann D, Ouassou K, Klingelh\u00f6fer D, Groneberg DA. Endometrial cancer: mapping the global landscape of research. J Transl Med. 2020;18:388. https:\/\/doi.org\/10.1186\/s12967-020-02525-2.","journal-title":"J Transl Med"},{"issue":"1","key":"4227_CR34","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1186\/s12951-024-02521-5","volume":"22","author":"Y Wu","year":"2024","unstructured":"Wu Y, Zhu M, Sun B, Chen Y, Huang Y, Gai J, et al. A humanized trivalent Nectin-4-targeting nanobody drug conjugate displays potent antitumor activity in gastric cancer. J Nanobiotechnol. 2024;22(1):256. https:\/\/doi.org\/10.1186\/s12951-024-02521-5.","journal-title":"J Nanobiotechnol"},{"issue":"3","key":"4227_CR35","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1007\/s10555-023-10113-2","volume":"42","author":"C Zhang","year":"2023","unstructured":"Zhang C, Sheng Y, Sun X, Wang Y. New insights for gynecological cancer therapies: from molecular mechanisms and clinical evidence to future directions. Cancer Metastasis Rev. 2023;42(3):891\u2013925. https:\/\/doi.org\/10.1007\/s10555-023-10113-2.","journal-title":"Cancer Metastasis Rev"},{"key":"4227_CR36","doi-asserted-by":"publisher","first-page":"1571800","DOI":"10.3389\/fimmu.2025.1571800","volume":"16","author":"Y Xu","year":"2025","unstructured":"Xu Y, Wang T, Liang X, Yang J, Zhang Y, Bao S. Global research trends and focus on immunotherapy for endometrial cancer: a comprehensive bibliometric insight and visualization analysis (2012\u20132024). Front Immunol. 2025;16:1571800. https:\/\/doi.org\/10.3389\/fimmu.2025.1571800.","journal-title":"Front Immunol"}],"container-title":["BMC Women's Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12905-025-04227-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12905-025-04227-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12905-025-04227-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T06:41:50Z","timestamp":1769064110000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12905-025-04227-8"}},"subtitle":["Title page"],"short-title":[],"issued":{"date-parts":[[2025,12,19]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4227"],"URL":"https:\/\/doi.org\/10.1186\/s12905-025-04227-8","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-7459698\/v1","asserted-by":"object"}]},"ISSN":["1472-6874"],"issn-type":[{"value":"1472-6874","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,19]]},"assertion":[{"value":"26 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The Aksaray University Clinical Research Ethics Committee approved this study (Decision No: 2022\/18\u2009\u2212\u200904). The study followed the Declaration of Helsinki. Written informed consent was obtained from all participants.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"46"}}